WO2023201370A3 - Co-assembled peptide granules for intracellular protein delivery - Google Patents

Co-assembled peptide granules for intracellular protein delivery Download PDF

Info

Publication number
WO2023201370A3
WO2023201370A3 PCT/US2023/065823 US2023065823W WO2023201370A3 WO 2023201370 A3 WO2023201370 A3 WO 2023201370A3 US 2023065823 W US2023065823 W US 2023065823W WO 2023201370 A3 WO2023201370 A3 WO 2023201370A3
Authority
WO
WIPO (PCT)
Prior art keywords
intracellular protein
granules
protein delivery
assembled peptide
peptide granules
Prior art date
Application number
PCT/US2023/065823
Other languages
French (fr)
Other versions
WO2023201370A8 (en
WO2023201370A2 (en
Inventor
Gregory Allan Hudalla
Renjie Liu
Original Assignee
University Of Florida Research Foundation, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Florida Research Foundation, Incorporated filed Critical University Of Florida Research Foundation, Incorporated
Publication of WO2023201370A2 publication Critical patent/WO2023201370A2/en
Publication of WO2023201370A3 publication Critical patent/WO2023201370A3/en
Publication of WO2023201370A8 publication Critical patent/WO2023201370A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Provided herein are co-assembling peptides which may form granules under stimulating conditions. Also provided herein are protein carrying granules. Further provided herein, are methods of making each of the co-assembling peptides and granules.
PCT/US2023/065823 2022-04-15 2023-04-14 Co-assembled peptide granules for intracellular protein delivery WO2023201370A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263331755P 2022-04-15 2022-04-15
US63/331,755 2022-04-15

Publications (3)

Publication Number Publication Date
WO2023201370A2 WO2023201370A2 (en) 2023-10-19
WO2023201370A3 true WO2023201370A3 (en) 2023-11-23
WO2023201370A8 WO2023201370A8 (en) 2024-09-26

Family

ID=88330428

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/065823 WO2023201370A2 (en) 2022-04-15 2023-04-14 Co-assembled peptide granules for intracellular protein delivery

Country Status (1)

Country Link
WO (1) WO2023201370A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180044379A1 (en) * 2016-08-09 2018-02-15 University Of Florida Research Foundation, Inc. Co-assembly peptides, nanostructures, and methods of making and using the same
US20220088221A1 (en) * 2019-01-12 2022-03-24 The Methodist Hospital Self-assembled peptide nanoparticle and use thereof
WO2022225987A1 (en) * 2021-04-19 2022-10-27 University Of Florida Research Foundation, Incorporated Agents for manufacture of co-assembling peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180044379A1 (en) * 2016-08-09 2018-02-15 University Of Florida Research Foundation, Inc. Co-assembly peptides, nanostructures, and methods of making and using the same
US20220088221A1 (en) * 2019-01-12 2022-03-24 The Methodist Hospital Self-assembled peptide nanoparticle and use thereof
WO2022225987A1 (en) * 2021-04-19 2022-10-27 University Of Florida Research Foundation, Incorporated Agents for manufacture of co-assembling peptides

Also Published As

Publication number Publication date
WO2023201370A8 (en) 2024-09-26
WO2023201370A2 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
MX2021011997A (en) Improved conjugation linkers.
EP2360176A3 (en) Hybrid and tandem expression of neisserial derived proteins
WO2003031462A3 (en) Nogo receptor-mediated blockade of axonal growth
MX348154B (en) IL-1ß BINDING ANTIBODIES AND FRAGMENTS THEREOF.
WO2001051520A9 (en) Nogo receptor-mediated blockade of axonal growth
EP1319023B8 (en) An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
EP4374913A3 (en) Novel human serum albumin mutant
WO2019222449A8 (en) Protein binding nkg2d, cd16 and a fibroblast activation protein
WO2020247388A3 (en) Il-2alpha receptor subunit binding compounds
MX2023001595A (en) Fusion proteins comprising milk proteins and compositions thereof.
WO2021072129A3 (en) Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
WO2005123760A3 (en) Treating cancer
WO2021087296A8 (en) Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
WO2006028561A3 (en) Novel purified fabi polypeptides from fransicella tularensis
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
WO2022272033A3 (en) Extended-release immune cell engaging proteins and methods of treatment
MX2020010071A (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria.
WO2023201370A3 (en) Co-assembled peptide granules for intracellular protein delivery
WO2022200390A3 (en) Glycan-mediated protein degradation
WO2006052775A3 (en) Peptide anti - tumor agent
MX2024003412A (en) Mrna regulon therapy for the treatment of haploinsufficiency disorders.
WO2020225799A3 (en) A method of decreasing concentration of tau (τ) protein and/or phosphorylated tau (τ) protein
WO2006078268A3 (en) A peptide that elicits neutralizing antibodies targeting the hiv co-receptor, ccr5
EP1557466A4 (en) Tumor antigen protein and utilization thereof
WO2024015981A3 (en) Therapeutic compositions and methods for age-related macular degeneration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23789205

Country of ref document: EP

Kind code of ref document: A2